AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Relay Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00DSS08L8
18.18▼ 0.16 (-0.87%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
18.34
Day's Range
17.68 – 18.27
52-Week Range
5.95 – 21.27
Volume
1.9M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
192
Exchange
XNAS
Listed
2020-07-16
Share count as of July 31, 2026

Relay Therapeutics, Inc. Common Stock (RLAY) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Relay Therapeutics, Inc. Common Stock (RLAY)
What is Relay Therapeutics, Inc. Common Stock's Market Cap?
Relay Therapeutics, Inc. Common Stock's Market Cap is $4.0B, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's Enterprise Value?
Relay Therapeutics, Inc. Common Stock's Enterprise Value is $3.9B, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's Price / Sales?
Relay Therapeutics, Inc. Common Stock's Price / Sales is 384.9×, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's EV / Revenue?
Relay Therapeutics, Inc. Common Stock's EV / Revenue is 373.2×, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's EV / EBITDA?
Relay Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's Revenue (TTM)?
Relay Therapeutics, Inc. Common Stock's Revenue (TTM) is $10.3M, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's Net Income (TTM)?
Relay Therapeutics, Inc. Common Stock's Net Income (TTM) is -$286.0M, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's EBITDA?
Relay Therapeutics, Inc. Common Stock's EBITDA is -$308.2M, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Relay Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.31, based on as-reported figures from SEC (XBRL) filings.
What is Relay Therapeutics, Inc. Common Stock's EBITDA Margin?
Relay Therapeutics, Inc. Common Stock's EBITDA Margin is -2978.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · RLAYAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
License and other revenue
YoY growth-48.3%-60.9%——
Total revenue
Operating expenses:
Research and development expenses
Change in fair value of contingent consideration liability———
General and administrative expenses
Total operating expenses
% of revenue26049.7%2719.7%966.1%—
Loss from operations
% of revenue-25949.7%-2619.7%-866.1%—
Other income:
Interest income
Other income (expense)—
Total other income, net
Net loss
% of revenue-23916.3%-2443.0%-784.1%—
Net loss per share, basic
Net loss per share, diluted